Sanofi SA was further buoyed by its best-selling drug Dupixent in the first quarter as sales reached €2.3 billion and the path was cleared for a possible new indication in the US. The Food and Drug Administration is to review Dupixent for the treatment of chronic spontaneous urticaria, also known as hives. If approved, it would be the drug’s eleventh US indication since it was first approved for eczema in 2017.
